

Corporate Medical Policy

Hepatitis C AHS – G2036

| | |
|-------------------------|-------------|
| File Name: | hepatitis_c |
| Origination: | 1/1/2019 |
| Last CAP Review: | 2/2021 |
| Next CAP Review: | 2/2022 |
| Last Review: | 2/2021 |

Description of Procedure or Service

Description

Hepatitis C is a liver infection caused by the Hepatitis C virus (HCV). Hepatitis C is a blood-borne virus that can be spread via sharing needles or other equipment to inject drugs as well as in inadequate infection control in healthcare settings (CDC, 2016).

Hepatitis C causes liver disease and inflammation. Chronic HCV infection can lead to hepatic damage, including cirrhosis and hepatocellular carcinoma, and is the most common cause of liver transplantation in the United States (AASLD, 2015).

Literature Review

The Centers for Disease Control and Prevention estimate that 3.2 million people in the United States have chronic hepatitis C (CDC, 2016a). Prevalence of the infection is highest in individuals born between 1945 and 1965. This rate is approximately six times higher than that seen in other adult age groups, and the CDC estimated approximately 41,200 new infections occurring each year (CDC, 2016b). Hepatitis C virus (HCV) infection is the most common reason for liver transplantation in adults in the U.S. and may lead to hepatocellular carcinoma (S. Chopra, 2018).

It is estimated that 20% of people with HCV infection will develop cirrhosis, and nearly 5% will die from liver disease resulting from the HCV infection. The number of deaths from hepatitis is increasing and is projected to continue to increase for several more decades unless treatment is scaled up considerably (Razavi et al., 2014). Although HCV infection is common, it is estimated that 50-75% of individuals who are infected are unaware of their infection as symptoms are absent or nonspecific until much later, and therefore do not receive the care and treatment that can mitigate progression to severe liver disease and possibly death (Hagan et al., 2006; Rein et al., 2012).

HCV is spread through exposure to blood of infected individuals. Such exposure includes injection drug use, blood transfusions (prior to 1992), and to a lesser extent, high-risk sexual behaviors. Additionally, being born to an HCV-infected mother, hemodialysis, intranasal drug use, tattoos, incarceration, needle sticks, and invasive procedures (prior to implementation of universal precautions) are also associated with increased risk of HCV infection. Some countries are experiencing a recent resurgence of HCV infection among young intravenous drug users and HIV-infected homosexual men (CDC, 2015a; Wandeler et al., 2015).

HCV is a small, positive-stranded RNA-enveloped virus with a highly variable genome (Simmonds, 2001). Assessment of the HCV genotype is crucial for management of the HCV infection. There are currently six major genotypes of HCV, and major treatment decisions (regimen, dosing, duration)

Hepatitis C AHS – G2036

vary from genotype to genotype (S. Chopra, Arora, Sanjeev, 2018a). Some regimens for one genotype (such as ledipasvir-sofosbuvir [“Harvoni”] for genotype 1) may not be effective for another (in this case, Harvoni may be used for genotypes 1, 4, 5, and 6 but not 2 or 3) (S. Chopra, Muir, Andrew, 2018; Lexicomp, 2019).

HCV is frequently asymptomatic, necessitating the need of strong screening procedures. As many as 50% of HCV-infected individuals are unaware of their diagnosis, and risk factors such as drug use or blood transfusions may increase risk of acquiring an HCV infection. Several expert groups, such as the CDC, have delineated screening recommendations in order to provide better care against the virus (S. Chopra, Arora, Sanjeev, 2018b).

Many point-of-care tests have been developed to diagnose hepatitis C efficiently. These point-of-care tests are particularly important for diagnoses in economically impoverished areas. Examples of these tests include OraQuick, TriDot and SDBioline. The OraQuick HCV test is a FDA approved point-of-care test which utilizes a fingerstick and a small whole blood sample to detect the virus. This test is reportedly more than 98% accurate and provides results in 20 minutes (OraSure, 2013). The 4th Generation HCV Tri-Dot is a rapid test which can detect all subtypes of HCV with 100% sensitivity and 98.9% specificity (JMitra&Co, 2015). This test uses human serum or plasma and can provide results in three minutes. Finally, the SDBioline is an immunochromatographic rapid test that can identify HCV antibodies in human blood, serum or plasma (Abbott, 2020). This test uses a safe fingerstick procedure to obtain a sample.

Hepatitis panel tests have also been developed. For example, the VIDAS® Hepatitis panel by BioMérieux tests for hepatitis A, B and C in less than two hours (BioMérieux, 2018). This panel includes nine automated assays and is a rapid, reliable and simple testing method.

A hepatitis C vaccine is currently not available although many vaccines are under development; barriers to the development of such a vaccine include virus diversity, a lack of knowledge of the immune responses when an infection occurs, and limited models for the testing of new vaccines (Ansaldi, Orsi, Sticchi, Bruzzone, & Icardi, 2014; Bailey, Barnes, & Cox, 2019). The World Health Organization hopes for a 90% reduction in new hepatitis C cases by the year 2030 (Bailey et al., 2019).

Management of HCV infection typically involves monitoring the effect of treatment. The goal of treatment is to achieve a “sustained virologic response” (SVR), which is defined as “an undetectable RNA level 12 weeks following the completion of therapy” (S. Chopra, Pockros, Paul, 2018). This measure is a proxy for elimination of HCV RNA. The assessment schedule may vary regimen to regimen, but the viral load is generally evaluated every few weeks (S. Chopra, Pockros, Paul, 2018).

Clinical Validity and Utility

Messina et al. (2015) performed a meta-analysis on the prevalence of HCV genotypes worldwide. The authors evaluated 1217 studies encompassing approximately 90% of the global population. They calculated genotype 1 to comprise 83.4 million cases (46.2% of all HCV cases), genotype 3 to comprise 54.3 million cases (30.1%), and genotypes 2, 4, and 6 to comprise a combined 22.8% cases. Genotype 5 comprised less than 1% of HCV cases. The diversity of genotypes also varied; the highest diversity is observed in China and South-East Asia, while in some countries, such as Egypt and Mongolia, almost all HCV infections are caused by a single genotype (Messina et al., 2015).

Inoue et al. (2017) described four HCV patients whose treatment failed. These four HCV patients had received a treatment regimen of daclatasvir plus asunaprevir, which is used for genotype 1b. However, these four patients were re-tested and found to have a different genotype; 3 patients had genotype 2 and the 4th patient had genotype 1a. The authors suggested that the daclatasvir plus asunaprevir regimen was ineffective for patients without genotype 1b (Inoue et al., 2017).

Hepatitis C AHS – G2036

Moreno et al. (2016) performed a cost analysis of expanded HCV coverage. Two scenarios were simulated, one with expanded fibrosis coverage to stage 2 fibrosis, and the other to all fibrosis cases. Over a 20-year simulation, treatment costs increased, but private payers experienced overall savings of \$10 billion to \$14 billion after treatment costs. A positive “spillover” benefit of \$400 million to Medicare was seen in the 5-year model, and a benefit of \$7 billion to Medicare was seen in the 20-year model (Moreno et al., 2016).

Linthicum et al. (2016) assessed the cost-effectiveness of expanding screening and treatment coverage over a 20-year horizon. The authors investigated three scenarios, each of which expanded coverage to a different stage of fibrosis. “Net social value” was the primary outcome evaluated, and it was calculated by the “value of benefits from improved quality-adjusted survival and reduced transmission minus screening, treatment, and medical costs.” Overall, the scenario with only fibrosis stage 3 and fibrosis stage 4 covered generated \$0.68 billion in social value, but the scenario with all fibrosis patients (stages 0-4) treated produced \$824 billion in social value. The authors also noted that the scenario with all fibrosis stages covered created net social value by year 9 whereas the scenario with only stages 3 and 4 covered needed all 20 years to break even (Linthicum et al., 2016).

Chen et al. (2019) completed a meta-analysis to research the relationship between type 2 diabetes mellitus development and patients with a HCV infection. Studies were included from 2010 to 2019. Five types of HCV individuals were incorporated in this study including those who were “non-HCV controls, HCV-cleared patients, chronic HCV patients without cirrhosis, patients with HCV cirrhosis and patients with decompensated HCV cirrhosis” (Chen et al., 2019). HCV infection was found to be a significant risk factor for type 2 diabetes mellitus development. Further, “HCV clearance spontaneously or through clinical treatment may immediately reduce the risk of the onset and development of T2DM [type 2 diabetes mellitus] (Chen et al., 2019).”

Saeed et al. (2020) completed a systematic review and meta-analysis of health utilities for patients diagnosed with a chronic hepatitis C infection. Health utility can be defined as a measure of health-related quality or general health status. A total of 51 studies comprised of 15,053 patients were included in this study. The researchers have found that “Patients receiving interferon-based treatment had lower utilities than those on interferon-free treatment (0.647 vs 0.733). Patients who achieved sustained virologic response (0.786) had higher utilities than those with mild to moderate CHC [chronic hepatitis C]. Utilities were substantially higher for patients in experimental studies compared to observational studies (Saeed et al., 2020).” Overall, these results show that chronic hepatitis C infections are significantly harming global health status based on the measurements provided by health utility instruments.

Applicable Federal Regulations

A search on the FDA website for “Hepatitis C” on 02/25/2020, yielded 30 results. Additionally, many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). As an LDT, the U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use.

******Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.***

Policy

BCBSNC will provide coverage for Hepatitis C testing when it is determined the medical criteria or reimbursement guidelines below are met.

Hepatitis C AHS – G2036

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When Hepatitis C testing is covered

Reimbursement for a one-time screening for Hepatitis C infection is allowed for adults between the ages of 18 years and 79 years.

Reimbursement for testing for Hepatitis C infection is allowed in the following situations:

- Illicit drug use: injection (current or ever, including those who injected only once)
- Illicit drug use: intranasal
- Receipt of clotting factor concentrates produced before 1987
- History of or current hemodialysis
- Evidence of liver disease (based on clinical presentation or persistently abnormal alanine aminotransferase (ALT) levels, or abnormal liver studies)
- Presence of HIV infection
- Receipt of an organ transplant before July 1992
- Receipt of a blood transfusion or blood component before July 1992
- Individuals notified that they received blood from a donor who later tested positive for an HCV infection
- History of incarceration
- Receipt of a tattoo in an unregulated setting

Reimbursement for HCV- testing based on a recognized exposure is allowed for:

- Healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood
- Children born to HCV-positive women
- Current sexual partners of HCV-infected persons

Reimbursement for one time testing for HCV genotype is allowed prior to initiation of treatment to guide selection of the most appropriate antiviral regimen.

In patients with acute HCV infection, monitoring HCV RNA reimbursement is allowed to determine spontaneous clearance of HCV infection versus persistence of infection. Testing can be performed every 4 to 8 weeks for 6 to 12 months.

Reimbursement for testing for HCV viral load, using a quantitative nucleic acid test, is allowed in the following situations:

- prior to initiation of HCV therapy, AND
- after 4 weeks of therapy AND
- at the end of treatment AND
- 12 weeks and 24 weeks after completion of treatment.

When Hepatitis C testing is not covered

Reimbursement is not allowed for Hepatitis C testing in all situations not outlined above.

Policy Guidelines

Centers for Disease Control and Prevention (CDC) (CDC, 2012, 2015b, 2020)

Hepatitis C AHS – G2036

The Centers for Disease Control and Prevention (CDC) recommends HCV testing in the following individuals:

- “Adults born from 1945 through 1965 should be tested once (without prior ascertainment of HCV risk factors)
- HCV testing is recommended for those who:
 - Currently injecting drugs
 - Ever injected drugs, including those who injected once or a few times many years ago
 - Have certain medical conditions, including persons:
 - who received clotting factor concentrates produced before 1987
 - who were ever on long-term hemodialysis
 - with persistently abnormal alanine aminotransferase levels (ALT)
 - who have HIV infection
 - Were prior recipients of transfusions or organ transplants, including persons who:
 - were notified that they received blood from a donor who later tested positive for HCV infection
 - received a transfusion of blood, blood components, or an organ transplant before July 1992
- HCV- testing based on a **recognized exposure** is recommended for:
 - Healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood
 - Children born to HCV-positive women

Note: For persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended (CDC, 2020).

Persons for whom routine HCV testing is of uncertain need include:

- Recipients of transplanted tissue (e.g., corneal, musculoskeletal, skin, ova, sperm)
- Intranasal cocaine and other non-injecting illegal drug users
- Persons with a history of tattooing or body piercing
- Persons with a history of multiple sex partners or sexually transmitted diseases
- Long-term steady sex partners of HCV-positive persons

Persons for whom routine HCV testing is not recommended (unless they have risk factors for infection):

- Health care, emergency medical, and public safety workers
- Pregnant women
- Household (non-sexual) contacts of HCV-positive persons
- The general population (CDC, 2015b, 2020)”

The CDC also notes that the initial HCV test should be “with an FDA-approved test for antibody to HCV.” A positive result for the HCV antibody indicates either a current infection or previous infection that has resolved. For those individuals, the CDC recommends testing by an FDA-approved HCV nucleic acid test (NAT) to differentiate between active infection and resolved infection. “Persons who test anti-HCV positive or have indeterminate antibody test results who are also positive by HCV NAT should be considered to have active HCV infection; these persons need referral for further medical evaluation and care”. Finally, the CDC also recommends repeat testing for individuals with ongoing risk behaviors (CDC, 2012).

United States Preventive Services Task Force (USPSTF, 2013)(Moyer, 2013; Owens et al., 2020; USPSTF, 2013)

Hepatitis C AHS – G2036

The United States Preventive Services Task Force (USPSTF) recommends HCV screening in adults aged 18 to 79 years (B recommendation).

American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) (AASLD-IDSA, 2017, 2018a, 2018b, 2019) (AASLD-IDSA, 2017, 2018a, 2018b, 2019)

- AASLD-IDSA guidelines recommend one-time HCV testing in the following situations:
 - “One-time, routine, opt out HCV testing is recommended for all individuals aged 18 years and older. Rating: I, B
 - One-time HCV testing should be performed for all persons less than 18 years old with behaviors, exposures, or conditions or circumstances associated with an increased risk of HCV infection (see below). Rating: I,B
 - Periodic repeat HCV testing should be offered to all persons with behaviors, exposures, or conditions or circumstances associated with an increased risk of HCV exposure (see below). Rating: IIa, C
 - Annual HCV testing is recommended for all persons who inject drugs and for HIV-infected men who have unprotected sex with men. Rating: IIa, C
- Other persons should be screened for risk factors for HCV infection, and one-time testing should be performed for all persons with behaviors, exposures, and conditions associated with an increased risk of HCV infection.
 1. Risk behaviors
 - Injection-drug use (current or ever, including those who injected once)
 - Intranasal illicit drug use
 - Men who have sex with men
 2. Risk exposures
 - Persons on long-term hemodialysis (ever)
 - Persons with percutaneous/parenteral exposures in an unregulated setting
 - Healthcare, emergency medical, and public safety workers after needlesticks, sharps, or mucosal exposures to HCV-infected blood
 - Children born to HCV-infected women
 - Prior recipients of transfusions or organ transplants, including persons who:
 - Were notified that they received blood from a donor who later tested positive for HCV infection
 - Received a transfusion of blood or blood components, or underwent an organ transplant before July 1992
 - Received clotting factor concentrates produced before 1987
 - Persons who were ever incarcerated
 3. Other considerations
 - HIV infection
 - Sexually active persons about to start pre-exposure prophylaxis (PreP) for HIV
 - Unexplained chronic liver disease and/or chronic hepatitis including elevated alanine aminotransferase levels
 - Solid organ donors (deceased and living) (AASLD-IDSA, 2019)”

Rating: Class I, Level B

Recommendations for Follow-up of Initial Testing

- “HCV-antibody testing with reflex HCV RNA polymerase chain reaction (PCR) is recommended for initial HCV testing. Rating: Class I, Level A
- Among persons with a negative HCV-antibody test who were exposed to HCV within the prior 6 months, HCV-RNA or follow-up HCV-antibody testing 6 months or longer after exposure is recommended. HCV-RNA testing can also be considered for immunocompromised persons. Rating: Class I, Level C

Hepatitis C AHS – G2036

- Among persons at risk of reinfection after previous spontaneous or treatment-related viral clearance, initial HCV-RNA testing is recommended because an HCV-antibody test is expected to be positive.” Rating: Class I, Level C
- Quantitative HCV-RNA testing is recommended prior to the initiation of antiviral therapy to document the baseline level of viremia (ie, baseline viral load). Rating: Class I, Level A
- HCV genotype testing may be considered for those in whom it may alter treatment recommendations. Rating: Class I, Level A
- If found to have positive results for anti-HCV test and negative results for HCV RNA by polymerase chain reaction (PCR), persons should be informed that they do not have evidence of current (active) HCV infection but are not protected from reinfection. Rating: Class I, Level A (AASLD-IDSA, 2019).”

For acute HCV infections, AASLD-IDSA issued the following recommendations:

- HCV antibody and HCV RNA testing are recommended when acute HCV infection is suspected due to exposure, clinical presentation, or elevated aminotransferase levels (Rating: Class I, Level C)
- Regular laboratory monitoring is recommended in the setting of acute HCV infection. Monitoring HCV RNA (eg, every 4 weeks to 8 weeks) for 6 months to 12 months is also recommended to determine spontaneous clearance of HCV infection versus persistence of infection (Rating: Class I, Level B)
- If a decision has been made to initiate treatment during the acute infection period, monitoring HCV RNA for at least 12 weeks to 16 weeks before starting treatment is recommended to allow for spontaneous clearance (Rating: Class IIa, Level C) (AASLD-IDSA, 2017).

For monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy, AASLD-IDSA issued the following recommendations:

- “HCV genotype and subtype and quantitative HCV RNA (HCV viral load) is recommended prior to initiation of antiviral therapy.” (Rating: Class I, Level C)
- “Hepatic function panels (defined as albumin, total and direct bilirubin, alanine aminotransferase [ALT], aspartate aminotransferase [AST], and alkaline phosphatase levels) are recommended before starting antiviral therapy.” (Rating: Class I, Level C)
- “Quantitative HCV viral load testing is recommended after 4 weeks of therapy and at 12 weeks following completion of therapy.” (Rating: Class I, Level B)
- “Quantitative HCV viral load testing can be considered at the end of treatment and 24 weeks or longer following the completion of therapy.” (Rating: Class I, Level B)
- Hepatic function panels are also recommended for monitoring of disease progression every 6 to 12 months in patients that did not achieve an SVR (AASLD-IDSA, 2018b).

Recommendations for Post-Treatment Follow-Up for Patients in Whom Treatment Failed

- “As part of prenatal care, all pregnant women should be tested for HCV infection, ideally at the initial visit. Rating: IIb, C (AASLD-IDSA, 2019)”

Recommendations for Monitoring HCV-Infected Women During Pregnancy

- “HCV RNA and routine liver function tests are recommended at initiation of prenatal care for HCV-antibody-positive pregnant women to assess the risk of mother-to-child transmission (MTCT) and degree of liver disease. Rating: I, B
- All pregnant women with HCV infection should receive prenatal and intrapartum care that is appropriate for their individual obstetric risk(s) as there is no currently known intervention to reduce MTCT. Rating: I, B
- In HCV-infected pregnant women with pruritus or jaundice, there should be a high index of suspicion for intrahepatic cholestasis of pregnancy (ICP) with subsequent assessment of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum bile acids.

Hepatitis C AHS – G2036

- HCV-infected women with cirrhosis should be counseled about the increased risk of adverse maternal and perinatal outcomes. Antenatal and perinatal care should be coordinated with a maternal-fetal medicine (ie, high-risk pregnancy) obstetrician (AASLD-IDSA, 2019).”

Assessment of Liver Disease Severity

A section focused on determining the severity of liver diseases associated with an HCV infection is also included as part of the background of these AASLD-IDSA guidelines. The authors state the following:

“The severity of liver disease associated with chronic HCV infection is a key factor in determining the initial and follow-up evaluation of patients. Noninvasive tests using serum biomarkers or imaging allow for accurate diagnosis of cirrhosis in most individuals (see pretreatment workup in *When and in Whom to Initiate HCV Therapy*). Liver biopsy is rarely required but may be considered if other causes of liver disease are suspected.

- Noninvasive methods frequently used to estimate liver disease severity include:
- Liver-directed physical exam (normal in most patients)
- Routine blood tests (eg, ALT, AST, albumin, bilirubin, international normalized ratio [INR], and CBC with platelet count)
- Serum fibrosis marker panels
- Transient elastography
- Liver imaging (eg, ultrasound or CT scan) (AASLD-IDSA, 2019)”

American Association for the Study of Liver Diseases (AASLD) (AASLD, 2014)

AASLD recommends not repeating Hepatitis C viral load testing outside of antiviral therapy, stating that “the results of virologic testing do not change clinical management or outcomes” (AASLD, 2014).

World Gastroenterology Organisation (WGO) (WGO, 2016)

The WGO has provided the following recommendations on hepatitis C screening:

- “It is recommended that HCV serology testing be offered to individuals who are part of a population with high HCV seroprevalence or who have a history of HCV risk exposure/behaviour. Strong recommendation, moderate quality of evidence
- It is suggested that nucleic acid testing for the detection of HCV RNA be performed directly following a positive HCV serological test to establish the diagnosis of chronic HCV infection, in addition to nucleic acid testing for HCV RNA as part of the assessment for starting treatment for HCV infection. Conditional recommendation, very low quality of evidence (WGO, 2016).”

The WGO also includes a table which shows the populations with a high HCV prevalence or who have a history of HCV risk. The following groups are included:

- “Persons who have received medical or dental interventions in health-care settings where infection control practices are substandard
- Persons who have received blood transfusions prior to the time when serological testing of blood donors for HCV was initiated or in countries where serological testing of blood donations for HCV is not routinely performed
- People who inject drugs (PWID)
- Persons who have had tattoos, body piercing or scarification procedures done where infection control practices are substandard
- Children born to mothers infected with HCV
- Persons with HIV infection

Hepatitis C AHS – G2036

- Persons who use/have used intranasal drugs
- Prisoners and previously incarcerated persons (WGO, 2016)”

Finally the WGO mentions liver function tests several times, stating that “A number of clinical considerations are important for the management of persons with chronic HCV infection”; further, “Pre-treatment evaluation of the risk of adverse events should be based on the patient’s clinical details, concomitant medications, and knowledge of treatment regimen to be administered. The potential for DDIs [drug-drug interactions] should be assessed before treatment, and a regimen that has a low risk of DDI selected. Standard laboratory tests that are assessed prior to treatment initiation include a full blood count (FBC), international normalized ratio (INR), renal function and liver function tests: ALT, AST, bilirubin, albumin and alkaline phosphatase (WGO, 2016).”

The WGO also mentions that “in persons with HCV infection being treated for TB, it is important to monitor liver function tests” and that “Baseline liver function tests for individuals with chronic liver disease are encouraged prior to initiating treatment for latent TB infection. For individuals with abnormal baseline test results, routine periodic laboratory testing should be carried out during the treatment of latent TB infection (WGO, 2016).”

World Health Organization (WHO) (WHO, 2017, 2018)

Recommendations on screening for HCV infection (WHO, 2017, 2018):

| Testing approach | Recommendations |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Focused testing in most affected populations | <p>In all settings (and regardless of whether delivered through facility- or community based testing), it is recommended that serological testing for HCV antibody (antiHCV) be offered with linkage to prevention, care and treatment services to the following:</p> <ul style="list-style-type: none"> • Adults and adolescents from populations most affected by HCV infection (i.e. who are either part of a population with high HCV seroprevalence or who have a history of exposure and/or high-risk behaviors for HCV infection); • Adults, adolescents and children with a clinical suspicion of chronic viral hepatitis (i.e. symptoms, signs, laboratory markers) (strong recommendation, low quality of evidence) <p><i>Note: Periodic re-testing using HCV NAT should be considered for those with ongoing risk of acquisition or reinfection.</i></p> |
| General population testing | <p>In settings with a $\geq 2\%$ (intermediate) or $\geq 5\%$ (high) HCV antibody seroprevalence in the general population, it is recommended that all adults have access to and be offered HCV serological testing with linkage to prevention, care and treatment services.</p> <p>General population testing approaches should make use of existing community- or facility-based testing opportunities or programs such as HIV or TB clinics, drug treatment services and antenatal clinics (conditional recommendation, low quality of evidence)</p> |
| Which Serological Assay to Use | <p>To test for serological evidence of past or present infection in adults, adolescents and children (>18 months of age), an HCV serological assay (antibody or antibody/antigen) using either a rapid diagnostic test (RDT) or laboratory-based immunoassay formats that meet minimum safety, quality and performance standards (with regard to both analytical and clinical sensitivity and specificity) is recommended.</p> <ul style="list-style-type: none"> • In settings where there is limited access to laboratory infrastructure and testing, and/or in populations where access to rapid testing would facilitate linkage to care and treatment, RDTs are |

Hepatitis C AHS – G2036

| | |
|--|------------------------------------------------------------------------|
| | recommended. (Strong recommendation, low/moderate quality of evidence) |
|--|------------------------------------------------------------------------|

Canadian Association for the Study of the Liver (CASL) (Shah et al., 2018)

The CASL has published new guidelines regarding management of HCV.

“Determination of HCV RNA, genotype and subtype (i.e., 1a v. 1b) is helpful in the management of patients with chronic HCV infection, and genotyping before starting therapy is still recommended.” Assessment of HCV genotype, HCV RNA, and resistance testing are recommended as part of initial workup (i.e. before initiation of therapy).

“In those with ongoing risk exposures, annual HCV RNA testing to assess for reinfection is suggested” (Shah et al., 2018).

Further, the CASL (Shah et al., 2018) includes the following routine bloodwork as a suggested work-up before beginning HCV therapy:

American Gastroenterological Association (AGA) (Jacobson, Lim, & Fried, 2017; Kanwal et al., 2017)

The AGA released best practice statements for care of patients with chronic HCV that have achieved a sustained virologic response (SVR).

- “SVR should be confirmed by undetectable HCV RNA at 12 weeks after completion of an all-oral DAA treatment regimen.”
- “Routine confirmation of SVR at 48 weeks post end of treatment is recommended. Testing for HCV RNA at 24 weeks post treatment should be considered on an individual patient basis.”
- “Routine testing for HCV RNA beyond 48 weeks after end of treatment to evaluate for late virologic relapse is not supported by available evidence; periodic testing for HCV RNA is recommended for patients with ongoing risk factors for reinfection” (Jacobson, Lim, & Fried, 2017).

The AGA has also released a “pathway” for HCV treatment (an algorithm).

Prior to treatment, the AGA recommends identifying the HCV genotype, as well as taking a hepatic function panel (defined as albumin, total and direct bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase).

For all three lengths of treatment courses (8, 12, 16 weeks), the AGA recommends assessing viral load and liver function (the same hepatic panel listed above) (Kanwal et al., 2017)

European Association for the Study of the Liver (EASL, 2018)

The EASL released guidelines on treatment of Hepatitis C. The EASL recommends:

- Screening of “populations at risk of infection, birth cohort testing, and general population testing in areas of intermediate to high seroprevalence ($\geq 2\%$ –5%)”
- “Liver disease severity must be assessed prior to therapy.”
- “HCV genotype and genotype 1 subtype must be assessed prior to treatment initiation. However, “testing for HCV resistance prior to treatment is not recommended” (EASL, 2018).

Canadian Task Force on Preventive Health Care (CTFPHC) (CTFPHC, 2017)

The CTFPHC has given the following recommendations:

- “We recommend against screening for HCV in adults who are not at elevated risk (strong recommendation, very low-quality evidence).

Hepatitis C AHS – G2036

- We recommend against screening for HCV in adults who are not at elevated risk (strong recommendation, very low-quality evidence) (CTFPHC, 2017).”

Society of Obstetricians and Gynecologists of Canada (SOGC) (Boucher & Gruslin, 2017)

The SOGC has published guidelines for the reproductive care of women living with a hepatitis C infection. These guidelines state that “Universal screening for HCV is not recommended, although targeted screening should be offered to all women falling into any at-risk category. Testing should take place following adequate counselling and informed consent of the patient (III B) (Boucher & Gruslin, 2017).”

Further, the SOGC also states that for care during pregnancy, “Antenatal care will need to be tailored individually to meet the specific needs of the woman's medical and obstetrical condition, including the monitoring of liver function (II-2 A) (Boucher & Gruslin, 2017).”

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable service codes: 86803, 86804, 87520, 87521, 87522, 87902, G0472

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources

AASLD-IDSA. (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology*, 62(3), 932-954. doi:10.1002/hep.27950

AASLD-IDSA. (2017). Management of Acute HCV Infection. Retrieved from <https://www.hcvguidelines.org/unique-populations/acute-infection>

AASLD-IDSA. (2018a). HCV Testing and Linkage to Care. Retrieved from <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

AASLD-IDSA. (2018b). Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy. Retrieved from <https://www.hcvguidelines.org/evaluate/monitoring>

AASLD-IDSA. (2019). HCV Testing and Linkage to Care. Retrieved from <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

AASLD. (2014). Retrieved from <http://www.choosingwisely.org/clinician-lists/american-association-study-liver-disease-hepatitis-c-viral-load-testing/>

Abbott. (2020). SD BIOLINE HCV. Retrieved from <https://www.alere.com/en/home/product-details/sd-bioline-hcv.html>

Ansaldi, F., Orsi, A., Sticchi, L., Bruzzone, B., & Icardi, G. (2014). Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. *World J Gastroenterol*, 20(29), 9633-9652. doi:10.3748/wjg.v20.i29.9633

Hepatitis C AHS – G2036

Bailey, J. R., Barnes, E., & Cox, A. L. (2019). Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. *Gastroenterology*, 156(2), 418-430. doi:10.1053/j.gastro.2018.08.060

BioMérieux. (2018). VIDAS® Hepatitis panel. Retrieved from <https://www.biomerieux.com.au/product/vidas-hepatitis-panel>

Boucher, M., & Gruslin, A. (2017). No. 96-The Reproductive Care of Women Living With Hepatitis C Infection. *J Obstet Gynaecol Can*, 39(7), e1-e25. doi:10.1016/j.jogc.2017.04.007

CDC. (2012). Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm>

CDC. (2015a). Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone — Indiana, 2015. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6416a4.htm>

CDC. (2015b). Testing Recommendations for Hepatitis C Virus Infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>

CDC. (2016a). Hepatitis C. Retrieved from <https://www.cdc.gov/dotw/hepatitisc/index.html>

CDC. (2016b). Surveillance for Viral Hepatitis – United States, 2016. Retrieved from <https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm>

CDC. (2020). Testing Recommendations for Hepatitis C Virus Infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>

Chen, Y., Ji, H., Shao, J., Jia, Y., Bao, Q., Zhu, J., . . . Shen, Y. (2019). Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. *Dig Dis Sci*. doi:10.1007/s10620-019-05918-7

Chopra, S. (2018). Clinical manifestations and natural history of chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C&topicRef=3673&source=see_link#H349503874

Chopra, S., Arora, Sanjeev. (2018a). Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/patient-evaluation-and-selection-for-antiviral-therapy-for-chronic-hepatitis-c-virus-infection?sectionName=HCV%20genotype&search=Hepatitis%20C&topicRef=89950&anchor=H620697012&source=see_link#H620697012

Chopra, S., Arora, Sanjeev. (2018b). Screening for chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/screening-for-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C%20screening&source=search_result&selectedTitle=1~79&usage_type=default&display_rank=1

Chopra, S., Muir, Andrew. (2018). Treatment regimens for chronic hepatitis C virus genotype 1 infection in adults. Retrieved from https://www.uptodate.com/contents/treatment-regimens-for-chronic-hepatitis-c-virus-genotype-1-infection-in-adults?search=Hepatitis%20C&topicRef=3668&source=see_link

Chopra, S., Pockros, Paul. (2018). Overview of the management of chronic hepatitis C virus infection. Retrieved from <https://www.uptodate.com/contents/overview-of-the-management-of-chronic-hepatitis-c-virus->

Hepatitis C AHS – G2036

[infection?search=Hepatitis%20C&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H9643992](https://www.cmaaj.ca/content/cmaj/189/16/E594.full.pdf)

CTFPHC. (2017). Recommendations on hepatitis C screening for adults. Retrieved from <https://www.cmaaj.ca/content/cmaj/189/16/E594.full.pdf>

EASL. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol*, 69(2), 461-511. doi:10.1016/j.jhep.2018.03.026

Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F., . . . Garfein, R. S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. *Public Health Rep*, 121(6), 710-719. doi:10.1177/003335490612100611

Inoue, J., Kanno, A., Wakui, Y., Miura, M., Kobayashi, T., Morosawa, T., . . . Shimosegawa, T. (2017). Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment. *Tohoku J Exp Med*, 241(1), 21-28. doi:10.1620/tjem.241.21

Jacobson, I. M., Lim, J. K., & Fried, M. W. (2017). American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. *Gastroenterology*, 152(6), 1578-1587. doi:10.1053/j.gastro.2017.03.018

JMitra&Co. (2015). HCV TRI-DOT. Retrieved from http://www.jmitra.co.in/ourdivision/diagnosticdivision/rapidtestkits/hcvrange/hcv_tri_dot.aspx

Kanwal, F., Bacon, B. R., Beste, L. A., Brill, J. V., Gifford, A. L., Gordon, S. C., . . . Younossi, Z. M. (2017). Hepatitis C Virus Infection Care Pathway—A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. *Gastroenterology*, 152(6), 1588-1598. doi:10.1053/j.gastro.2017.03.039

Lexicomp. (2019). Ledipasvir and sofosbuvir: Drug information. Retrieved from https://www.uptodate.com/contents/ledipasvir-and-sofosbuvir-drug-information?search=Hepatitis%20C&topicRef=16592&source=see_link

Linthicum, M. T., Gonzalez, Y. S., Mulligan, K., Moreno, G. A., Dreyfus, D., Juday, T., . . . Brookmeyer, R. (2016). Value of expanding HCV screening and treatment policies in the United States. *Am J Manag Care*, 22(6 Spec No.), Sp227-235. Retrieved from <https://www.ajmc.com/journals/issue/2016/2016-5-vol22-sp/value-of-expanding-hcv-screening-and-treatment-policies-in-the-united-states?p=1>

Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E. (2015). Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*, 61(1), 77-87. doi:10.1002/hep.27259

Moreno, G. A., Mulligan, K., Huber, C., Linthicum, M. T., Dreyfus, D., Juday, T., . . . Lakdawalla, D. N. (2016). Costs and spillover effects of private insurers' coverage of hepatitis C treatment. *Am J Manag Care*, 22(6 Spec No.), Sp236-244. Retrieved from <https://www.ajmc.com/journals/issue/2016/2016-5-vol22-sp/costs-and-spillover-effects-of-private-insurers-coverage-of-hepatitis-c-treatment?p=1>

Moyer, V. A. (2013). Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*, 159(5), 349-357. doi:10.7326/0003-4819-159-5-201309030-00672

OraSure. (2013). OraQuick® HCV test Retrieved from <https://www.orasure.com/products-infectious/products-infectious-oraquick-hcv.asp>

Hepatitis C AHS – G2036

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *Jama*. doi:10.1001/jama.2020.1123

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., . . . Estes, C. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat, 21 Suppl 1*, 34-59. doi:10.1111/jvh.12248

Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., . . . Weinbaum, C. M. (2012). The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. *Ann Intern Med, 156*(4), 263-270. doi:10.7326/0003-4819-156-4-201202210-00378

Saeed, Y. A., Phoon, A., Bielecki, J. M., Mitsakakis, N., Bremner, K. E., Abrahamyan, L., . . . Wong, W. W. L. (2020). A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. *Value Health, 23*(1), 127-137. doi:10.1016/j.jval.2019.07.005

Shah, H., Bilodeau, M., Burak, K. W., Cooper, C., Klein, M., Ramji, A., . . . Feld, J. J. (2018). The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. *Canadian Medical Association Journal, 190*(22), E677. doi:10.1503/cmaj.170453

Simmonds, P. (2001). Reconstructing the origins of human hepatitis viruses. *Philos Trans R Soc Lond B Biol Sci, 356*(1411), 1013-1026. doi:10.1098/rstb.2001.0890

USPSTF. (2013). Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med, 159*(5), 349-357. doi:10.7326/0003-4819-159-5-201309030-00672

Wandeler, G., Schlauri, M., Jaquier, M. E., Rohrbach, J., Metzner, K. J., Fehr, J., . . . Yerly, S. (2015). Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. *Open Forum Infect Dis, 2*(1), ofv026. doi:10.1093/ofid/ofv026

WGO. (2016). WHO Guidelines Approved by the Guidelines Review Committee. In *Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version*. Geneva: World Health Organization. WHO. (2017). *GUIDELINES ON HEPATITIS B AND C TESTING*.

WHO. (2018). GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION. Retrieved from <https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1>

Policy Implementation/Update Information

1/1/19 New policy developed. BCBSNC will provide coverage for hepatitis C testing when it is determined to be medically necessary because the medical criteria and guidelines are met. Medical Director review 1/1/2019. Policy noticed 1/1/2019 for effective date 4/1/2019. (sk)

10/1/19 Reviewed by Avalon 2nd Quarter 2019 CAB. Literature Review and Applicable Federal Regulations updated. Policy Guidelines updated. References updated. Coding table removed from the Billing/Coding section of the policy. Medical Director review 9/2019. (sk)

10/29/19 Wording in the Policy, When Covered, and/or Not Covered section(s) changed from Medical Necessity to Reimbursement language, where needed. (gm)

Hepatitis C AHS – G2036

3/10/20 Specialty Matched Consultant Advisory Panel review 2/19/2020. (sk)

7/28/20 Reviewed by Avalon 2nd Quarter 2020 CAB. Medical Director review 7/2020. Literature Review and Applicable Federal Regulations updated. Description section updated. Policy Guidelines updated. References updated. (bb)

3/9/21 Specialty Matched Consultant Advisory Panel review 2/17/2021. (sk)

Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.